X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel

Stifel lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $7.50 from $9 and keeps a Buy rating on the shares. The firm updated the company’s model post the earnings report and corporate update. The reduced target reflects revised financing assumptions, including the impact of X4’s October financing, the analyst tells investors in a research note.